Phase II study of cytarabine in Hodgkin's disease

José Thomas, Ben de Pauw, Anton Hagenbeek, Reinier Somers, Patrice Carde, Umberto Tirelli, Nicole Duez

Research output: Contribution to journalArticle

Abstract

Cytarabine was administered to 24 patients with previously treated Hodgkin's disease in the EORTC Lymphoma Cooperative Group. The drug was administered at the dose of 80 mg/m2 subcutaneously twice a day on 5 consecutive days every 3 weeks. The overall response rate was 17.6% (3 responses among 17 evaluable patients) with a short duration (2-6 months). The main toxicity was myelosuppression. Our experience in the EORTC Lymphoma Cooperative Group could not demonstrate a significant activity at this dose and schedule in Hodgkin's disease.

Original languageEnglish
Pages (from-to)857-859
Number of pages3
JournalEuropean Journal of Cancer
Volume28
Issue number4-5
DOIs
Publication statusPublished - 1992

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Phase II study of cytarabine in Hodgkin's disease'. Together they form a unique fingerprint.

  • Cite this

    Thomas, J., de Pauw, B., Hagenbeek, A., Somers, R., Carde, P., Tirelli, U., & Duez, N. (1992). Phase II study of cytarabine in Hodgkin's disease. European Journal of Cancer, 28(4-5), 857-859. https://doi.org/10.1016/0959-8049(92)90133-M